Literature DB >> 19331830

Residues in the alternative reading frame tumor suppressor that influence its stability and p53-independent activities.

Anne di Tommaso1, Jussara Hagen, Van Tompkins, Viviane Muniz, Amel Dudakovic, Alain Kitzis, Veronique Ladeveze, Dawn E Quelle.   

Abstract

The Alternative Reading Frame (ARF) protein suppresses tumorigenesis through p53-dependent and p53-independent pathways. Most of ARF's anti-proliferative activity is conferred by sequences in its first exon. Previous work showed specific amino acid changes occurred in that region during primate evolution, so we programmed those changes into human p14ARF to assay their functional impact. Two human p14ARF residues (Ala(14) and Thr(31)) were found to destabilize the protein while two others (Val(24) and Ala(41)) promoted more efficient p53 stabilization and activation. Despite those effects, all modified p14ARF forms displayed robust p53-dependent anti-proliferative activity demonstrating there are no significant biological differences in p53-mediated growth suppression associated with simian versus human p14ARF residues. In contrast, p53-independent p14ARF function was considerably altered by several residue changes. Val(24) was required for p53-independent growth suppression whereas multiple residues (Val(24), Thr(31), Ala(41) and His(60)) enabled p14ARF to block or reverse the inherent chromosomal instability of p53-null MEFs. Together, these data pinpoint specific residues outside of established p14ARF functional domains that influence its expression and signaling activities. Most intriguingly, this work reveals a novel and direct role for p14ARF in the p53-independent maintenance of genomic stability.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19331830      PMCID: PMC2665200          DOI: 10.1016/j.yexcr.2009.01.010

Source DB:  PubMed          Journal:  Exp Cell Res        ISSN: 0014-4827            Impact factor:   3.905


  54 in total

1.  An N-terminal p14ARF peptide blocks Mdm2-dependent ubiquitination in vitro and can activate p53 in vivo.

Authors:  C A Midgley; J M Desterro; M K Saville; S Howard; A Sparks; R T Hay; D P Lane
Journal:  Oncogene       Date:  2000-05-04       Impact factor: 9.867

2.  Cancer-associated mutations at the INK4a locus cancel cell cycle arrest by p16INK4a but not by the alternative reading frame protein p19ARF.

Authors:  D E Quelle; M Cheng; R A Ashmun; C J Sherr
Journal:  Proc Natl Acad Sci U S A       Date:  1997-01-21       Impact factor: 11.205

3.  Database of p53 gene somatic mutations in human tumors and cell lines: updated compilation and future prospects.

Authors:  P Hainaut; T Soussi; B Shomer; M Hollstein; M Greenblatt; E Hovig; C C Harris; R Montesano
Journal:  Nucleic Acids Res       Date:  1997-01-01       Impact factor: 16.971

4.  Contribution of two independent MDM2-binding domains in p14(ARF) to p53 stabilization.

Authors:  M A Lohrum; M Ashcroft; M H Kubbutat; K H Vousden
Journal:  Curr Biol       Date:  2000-05-04       Impact factor: 10.834

5.  Cooperative signals governing ARF-mdm2 interaction and nucleolar localization of the complex.

Authors:  J D Weber; M L Kuo; B Bothner; E L DiGiammarino; R W Kriwacki; M F Roussel; C J Sherr
Journal:  Mol Cell Biol       Date:  2000-04       Impact factor: 4.272

6.  Sumoylation induced by the Arf tumor suppressor: a p53-independent function.

Authors:  Kenji Tago; Susanna Chiocca; Charles J Sherr
Journal:  Proc Natl Acad Sci U S A       Date:  2005-05-16       Impact factor: 11.205

7.  ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways.

Authors:  Y Zhang; Y Xiong; W G Yarbrough
Journal:  Cell       Date:  1998-03-20       Impact factor: 41.582

8.  Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest.

Authors:  D E Quelle; F Zindy; R A Ashmun; C J Sherr
Journal:  Cell       Date:  1995-12-15       Impact factor: 41.582

9.  Functional and physical interactions of the ARF tumor suppressor with p53 and Mdm2.

Authors:  T Kamijo; J D Weber; G Zambetti; F Zindy; M F Roussel; C J Sherr
Journal:  Proc Natl Acad Sci U S A       Date:  1998-07-07       Impact factor: 11.205

10.  Differential requirement for p19ARF in the p53-dependent arrest induced by DNA damage, microtubule disruption, and ribonucleotide depletion.

Authors:  S H Khan; J Moritsugu; G M Wahl
Journal:  Proc Natl Acad Sci U S A       Date:  2000-03-28       Impact factor: 11.205

View more
  16 in total

1.  The ARF tumor suppressor inhibits tumor cell colonization independent of p53 in a novel mouse model of pancreatic ductal adenocarcinoma metastasis.

Authors:  Viviane Palhares Muniz; J Matthew Barnes; Seema Paliwal; Xuefeng Zhang; Xiaoyun Tang; Songhai Chen; Kokou D Zamba; Joseph J Cullen; David K Meyerholz; Shari Meyers; J Nathan Davis; Steven R Grossman; Michael D Henry; Dawn E Quelle
Journal:  Mol Cancer Res       Date:  2011-06-02       Impact factor: 5.852

2.  RABL6A promotes G1-S phase progression and pancreatic neuroendocrine tumor cell proliferation in an Rb1-dependent manner.

Authors:  Jussara Hagen; Viviane P Muniz; Kelly C Falls; Sara M Reed; Agshin F Taghiyev; Frederick W Quelle; Francoise A Gourronc; Aloysius J Klingelhutz; Heather J Major; Ryan W Askeland; Scott K Sherman; Thomas M O'Dorisio; Andrew M Bellizzi; James R Howe; Benjamin W Darbro; Dawn E Quelle
Journal:  Cancer Res       Date:  2014-10-01       Impact factor: 12.701

3.  Differential effects on ARF stability by normal versus oncogenic levels of c-Myc expression.

Authors:  Delin Chen; Ning Kon; Jiayun Zhong; Pingzhao Zhang; Long Yu; Wei Gu
Journal:  Mol Cell       Date:  2013-06-06       Impact factor: 17.970

4.  TRIM28 Is an E3 Ligase for ARF-Mediated NPM1/B23 SUMOylation That Represses Centrosome Amplification.

Authors:  Shu Hui Neo; Yoko Itahana; Jennifer Alagu; Mayumi Kitagawa; Alvin Kunyao Guo; Sang Hyun Lee; Kai Tang; Koji Itahana
Journal:  Mol Cell Biol       Date:  2015-06-08       Impact factor: 4.272

5.  RABL6A inhibits tumor-suppressive PP2A/AKT signaling to drive pancreatic neuroendocrine tumor growth.

Authors:  Shaikamjad Umesalma; Courtney A Kaemmer; Jordan L Kohlmeyer; Blake Letney; Angela M Schab; Jacqueline A Reilly; Ryan M Sheehy; Jussara Hagen; Nitija Tiwari; Fenghuang Zhan; Mariah R Leidinger; Thomas M O'Dorisio; Joseph Dillon; Ronald A Merrill; David K Meyerholz; Abbey L Perl; Bart J Brown; Terry A Braun; Aaron T Scott; Timothy Ginader; Agshin F Taghiyev; Gideon K Zamba; James R Howe; Stefan Strack; Andrew M Bellizzi; Goutham Narla; Benjamin W Darbro; Frederick W Quelle; Dawn E Quelle
Journal:  J Clin Invest       Date:  2019-03-04       Impact factor: 14.808

6.  Oncogenic RABL6A promotes NF1-associated MPNST progression in vivo.

Authors:  Jordan L Kohlmeyer; Courtney A Kaemmer; Joshua J Lingo; Ellen Voigt; Mariah R Leidinger; Gavin R McGivney; Amanda Scherer; Stacia L Koppenhafer; David J Gordon; Patrick Breheny; David K Meyerholz; Munir R Tanas; Rebecca D Dodd; Dawn E Quelle
Journal:  Neurooncol Adv       Date:  2022-04-09

7.  A conserved domain in exon 2 coding for the human and murine ARF tumor suppressor protein is required for autophagy induction.

Authors:  Anna Budina-Kolomets; Robert D Hontz; Julia Pimkina; Maureen E Murphy
Journal:  Autophagy       Date:  2013-08-07       Impact factor: 16.016

8.  ARF inhibits the growth and malignant progression of non-small-cell lung carcinoma.

Authors:  S E Busch; R D Moser; K E Gurley; K S Kelly-Spratt; H D Liggitt; C J Kemp
Journal:  Oncogene       Date:  2013-06-10       Impact factor: 9.867

9.  Mimicking p14ARF phosphorylation influences its ability to restrain cell proliferation.

Authors:  Maria Vivo; Michela Ranieri; Federica Sansone; Cristina Santoriello; Raffaele A Calogero; Viola Calabrò; Alessandra Pollice; Girolama La Mantia
Journal:  PLoS One       Date:  2013-01-07       Impact factor: 3.240

10.  NMI mediates transcription-independent ARF regulation in response to cellular stresses.

Authors:  Zengpeng Li; Jingjing Hou; Li Sun; Taoyong Wen; Liqin Wang; Xinmeng Zhao; Qingqing Xie; Si Qing Zhang
Journal:  Mol Biol Cell       Date:  2012-10-03       Impact factor: 4.138

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.